CANCER CACHEXIA. Barry J A Laird Clinician Scientist in Palliative Medicine, University of Edinburgh & European Palliative Care Research Centre

Size: px
Start display at page:

Download "CANCER CACHEXIA. Barry J A Laird Clinician Scientist in Palliative Medicine, University of Edinburgh & European Palliative Care Research Centre"

Transcription

1 CANCER CACHEXIA Barry J A Laird Clinician Scientist in Palliative Medicine, University of Edinburgh & European Palliative Care Research Centre Consultant in Palliative Medicine BWoSCC and Edinburgh Cancer Centre, UK

2 Acknowledgements University of Edinburgh Prof Ken Fearon, Prof Marie Fallon NTNU Prof P Klepstad, Prof S Kaasa, Prof P Fayers, Prof M Hjermstad University of Glasgow Prof D McMillan

3 Current standard of care in cancer cachexia? What are the licensed treatments for cancer cachexia? Dexamethasone Megesterol

4 A well designed study to evaluate the benefit of nutritional support in patients with weight loss receiving chemotherapy is needed PJ Ross et al 2004

5

6 The relationship between clinic-pathological factors and survival in patients with metastatic lung cancer (n=390) Parameter n % Univariate Multivariate Sex (M/F) 341/ / ( ) Age ( 65/ 65-74/ 74years) 154 /150/ /38.5/ ( ) HR (95% CI) p-value HR (95% CI) p-value Tumour type (NSCLC vs SCLC) 288/ / ( ) Weight loss (%) Category in past 3 months (1/2) a Performance Status (ECOG) (0-1/2/3/4) 195/ / ( ) /75/31/ /19.2/7.9/ ( ) < ( ) <0.001 mgps (0/ 1/ 2) 103/183/ /46.9/ ( ) < ( ) <0.001

7

8 Pathophysiology There have been great advances in the knowledge of cachexia pathophysiology This has lead to an increased understanding that cachexia is a distinct entity and must be treated as such

9 ANABOLIC BLOCKADE Systemic Inflammatory Response Cachexia Anorexia Physical Inactivity

10 Pro-inflammatory NORMAL Anti-inflammatory CANCER CACHEXIA Anti-inflammatory Pro-inflammatory

11 Inflammation & Cancer Inflammation predisposes to certain tumour types Inflammation implicated in oncogenic mutations & experimental animal models of tumour development 1 Inflammation can be a result of cancer. Targeting inflammation can reduce cancer risk and cancer spread. 7 th hallmark of cancer

12

13

14 Why has research in cachexia been slow? Unimodal therapy trials Prerequisite of oncology trials Late phase You are not eligible if you are taking part in another trial fastidious vs pragmatic trials gatekeeping Limited pharmaceutical funding Lack of a consensus definition

15 Volume 12, Issue 5, May 2011, P A multifactorial syndrome characterised by an on-going muscle loss (with or without fat loss) that cannot be fully reversed by nutritional support and leads to progressive functional impairment. The pathophysiology is characterized by a negative protein and energy balance driven by a variable combination of reduced nutritional intake and abnormal metabolism

16 Pre-cachexia Cachexia Refractory-cachexia Death Weight loss <5% Anorexia & metabolic change Weight loss>5% or BMI<20 and weight loss >2% or sarcopenia and weight loss >2% Variable degree of cachexia. Cancer disease both procatabolic and not responsive to anti-cancer treatment. Low PS, survival <3 months

17 Multimodal Therapy: High protein nutrition Anti-inflammatory agents to down regulate the APPR Routine mobilisation programmes to prevent deconditioning and encourage physical activity-induced stimulation of post prandial anabolism. Mantovani G, Maccio A, Madeddu C, et al. Randomized phase III clinical trial of five different arms of treatment in 332 patients with cancer cachexia. Oncologist 2010;15:200-11

18 Multimodal Intervention Critical pre-cachexic phase Combined with anti-cancer therapy

19 premenac Study A multicentre, open, randomized phase II study comparing a multimodal intervention (oral nutritional supplements, celecoxib and physical exercise) for cachexia versus standard cancer care. (EudraCT number: ) Funding EU FP6 framework

20 Identification Consent Treatment Arm (Multimodal intervention + Standard cancer care) Control Arm (Standard cancer care) Week 0 Week 6 Participants are offered same treatment as treatment arm (Multimodal intervention) Week 12

21 Multimodal Intervention (1) - Nutrition Aim: promote energy balance & ensure optimal protein intake Dietician led interview targets set. Information on dietary intake assessed. Advice given to modify diet to achieve targets Oral nutritional supplements 2 cartons (2x 220mls) per day of ProSURE. Contains 1.1g of EPA per carton. Energy and protein dense. Balstad, T.R., et al., Dietary treatment of weight loss in patients with advanced cancer and cachexia: A systematic literature review. Crit Rev Oncol Hematol, Baldwin, C., et al., Oral nutritional interventions in malnourished patients with cancer: a systematic review and meta-analysis. J Natl Cancer Inst, (5): p Cerchietti, L.C., A.H. Navigante, and M.A. Castro, Effects of eicosapentaenoic and docosahexaenoic n-3 fatty acids from fish oil and preferential Cox-2 inhibition on systemic syndromes in patients with advanced lung cancer. Nutr Cancer, (1): p

22 Multimodal Intervention (2) - Exercise Aim: to stabilize muscle mass, strength and improve physical performance Physiotherapist initial instruction and assessment Aerobic minimum 2 x 30 minute sessions per week (Borg scale 12-14) Resistance tailored 0.5-5kg weights. 3x20 minute sessions per week. Increasing weight over period of study Stene GB, Helbostad JL, Balstad TR, Riphagen, II, Kaasa S, Oldervoll LM. Effect of physical exercise on muscle mass and strength in cancer patients during treatment--a systematic review. Crit Rev Oncol Hematol

23 Multimodal Intervention (3) - COXII Aim: to target overproduction of inflammatory cytokines Celecoxib most studied, may have beneficial effects in cachexia Dose 300mg per day. Cerchietti, L.C., A.H. Navigante, and M.A. Castro, Effects of eicosapentaenoic and docosahexaenoic n-3 fatty acids from fish oil and preferential Cox-2 inhibition on systemic syndromes in patients with advanced lung cancer. Nutr Cancer, (1): p Maccio A, Madeddu C, Gramignano G, et al. A randomized phase III clinical trial of a combined treatment for cachexia in patients with gynecological cancers: evaluating the impact on metabolic and inflammatory profiles and quality of life. Gynecol Oncol 2012;124: Solheim, T.S., et al., Non-steroidal anti-inflammatory treatment in cancer cachexia: A systematic literature review. Acta Oncol, 2012.

24 Endpoints Primary Feasibility, recruitment, retention Secondary LBM, weight, activity, nutritional, toxicity, anti-cancer therapy

25 Antiinflammatories Systemic Inflammatory Response Nutritional Intake Cachexia Exercise Anorexia Immunomodulation! Physical Inactivity

26 Cachexia treatment hierarchy 1. Anti-neoplastic therapy 2. Target inflammation 3. Target factors affecting food and activity 4. Optimise nutritional intake 5. Promote activity

27

Dr Barry Laird Clinician Scientist in Palliative Medicine University of Edinburgh and the European Palliative Care Research Centre (PRC)

Dr Barry Laird Clinician Scientist in Palliative Medicine University of Edinburgh and the European Palliative Care Research Centre (PRC) 1 Dr Barry Laird Clinician Scientist in Palliative Medicine University of Edinburgh and the European Palliative Care Research Centre (PRC) 2 Acknowledgements Prof Marie Fallon (group lead EPAS) University

More information

Multimodal cachexia management

Multimodal cachexia management Multimodal cachexia management Dr Martin Chasen MBChB FCP(SA) MPhil(Pall Care) Medical Oncologist/Director of Palliative care William Osler Health Services Toronto CANADA Do you have anything that you

More information

ESPEN Congress Geneva 2014 LLL LIVE COURSE: NUTRITIONAL SUPPORT IN CANCER. Multimodal therapy of cancer cachexia K. Fearon (UK)

ESPEN Congress Geneva 2014 LLL LIVE COURSE: NUTRITIONAL SUPPORT IN CANCER. Multimodal therapy of cancer cachexia K. Fearon (UK) ESPEN Congress Geneva 2014 LLL LIVE COURSE: NUTRITIONAL SUPPORT IN CANCER Multimodal therapy of cancer cachexia K. Fearon (UK) Multimodal therapy for cancer cachexia KCH Fearon Learning objectives Understand

More information

Nutritional requirements in advanced cancer patients

Nutritional requirements in advanced cancer patients Nutritional requirements in advanced cancer patients Paula Ravasco p.ravasco@fmedicina.ulisboa.pt Laboratory of Nutrition Faculty of Medicine of the University of Lisbon Medical School of Lisbon Portugal

More information

Nutritional Support in Cancer Topic 26

Nutritional Support in Cancer Topic 26 Nutritional Support in Cancer Topic 26 Module 26.3 Multimodal Therapy for Cancer Cachexia Kenneth Fearon, MD, FRCS(Glas), FRCS(Ed), FRCS(Eng), Professor of Surgical Oncology, Clinical Surgery, University

More information

The use of omega-3 fatty acids in the management of cancer cachexia. Rhys White Principal Oncology Dietitian Guys and St Thomas NHS Foundation Trust

The use of omega-3 fatty acids in the management of cancer cachexia. Rhys White Principal Oncology Dietitian Guys and St Thomas NHS Foundation Trust The use of omega-3 fatty acids in the management of cancer cachexia Rhys White Principal Oncology Dietitian Guys and St Thomas NHS Foundation Trust Overview Cancer cachexia Clinical features Pathogenesis

More information

ESPEN guidelines: Nutritional interventions in advanced cancer care. -An overview and pending research questions

ESPEN guidelines: Nutritional interventions in advanced cancer care. -An overview and pending research questions 1 ESPEN guidelines: Nutritional interventions in advanced cancer care -An overview and pending research questions Tora Skeidsvoll Solheim, MD, PhD Oslo, October 2017 2 3 Definition of cachexia Cancer cachexia

More information

THE UNIVERSITY of EDINBURGH

THE UNIVERSITY of EDINBURGH THE UNIVERSITY of EDINBURGH Professor Kenneth Fearon MB ChB(Hons), MD, FRCPS (Glasgow), FRCS (Edinburgh), FRCS (England) Memorial Cancer Cachexia Symposium Royal Society of Edinburgh, George Street, Edinburgh

More information

A randomized phase II feasibility trial of a multimodal intervention for the management of cachexia in lung and pancreatic cancer

A randomized phase II feasibility trial of a multimodal intervention for the management of cachexia in lung and pancreatic cancer Journal of Cachexia, Sarcopenia and Muscle (2017) Published online in Wiley Online Library (wileyonlinelibrary.com) ORIGINAL ARTICLE A randomized phase II feasibility trial of a multimodal intervention

More information

Cancer cachexia: assessment and classification. KCH Fearon University of Edinburgh Scotland

Cancer cachexia: assessment and classification. KCH Fearon University of Edinburgh Scotland Cancer cachexia: assessment and classification KCH Fearon University of Edinburgh Scotland 1 What is the cancer cachexia phenotype?...the shoulders, clavicles, chest and thighs melt away. This illness

More information

Horizon Scanning Centre November Enobosarm (Ostarine) for cachexia in patients with advanced non-small cell lung cancer first line

Horizon Scanning Centre November Enobosarm (Ostarine) for cachexia in patients with advanced non-small cell lung cancer first line Horizon Scanning Centre November 2012 Enobosarm (Ostarine) for cachexia in patients with advanced non-small cell lung cancer first line SUMMARY NIHR HSC ID: 5206 This briefing is based on information available

More information

Nutrition support for sarcopenia in cancer patients

Nutrition support for sarcopenia in cancer patients Nutrition support for sarcopenia in cancer patients Kalliopi Anna Poulia, RD, MMedSci, PhD Clinical Nutritionist-Dietitian, Laiko General Hospital of Athens Vice President of the Hellenic Dietetic Association

More information

A new era of therapeutics for cancer cachexia. Cachexia is a continuum with 3 stages of clinical relevance

A new era of therapeutics for cancer cachexia. Cachexia is a continuum with 3 stages of clinical relevance A new era of therapeutics for cancer cachexia I. Depletion of Reserves II. Limitation of food intake III. Catabolic Drivers IV. Impact and outcomes Vickie Baracos PhD Professor and Alberta Cancer Foundation

More information

Classification of (cancer) cachexia: Any improvements to expect?

Classification of (cancer) cachexia: Any improvements to expect? 6 th Research Congress of EAPC Glasgow, June 11th 2010 Session Cachexia of EPCRC and EAPC RN Classification of (cancer) cachexia: Any improvements to expect? The joint work of many persons involved, thank

More information

Nutritional Support in Cancer

Nutritional Support in Cancer Nutritional Support in Cancer Topic 26 Module 26.4 Pharmacological and Multimodal Therapy for Cancer Cachexia Learning Objectives Ingvar Bosaeus Kenneth Fearon Grant Stewart Comprehend the importance of

More information

Combination therapy in cachexia

Combination therapy in cachexia Review Article Combination therapy in cachexia Egidio Del Fabbro Virginia Commonwealth University, Richmond, VA, USA Correspondence to: Egidio Del Fabbro, MD. Virginia Commonwealth University, 1101 E Marshall

More information

The Challenge of Cancer Cachexia

The Challenge of Cancer Cachexia The Challenge of Cancer Cachexia Jeffrey Crawford, MD George Barth Geller Professor for Research in Cancer Co-Director, Solid Tumor Therapeutics Program Duke Cancer Institute Disclosures Advisory Board/Consultant:

More information

Single Technology Appraisal (STA) Anamorelin for treating cachexia and anorexia in people with non-small-cell lung cancer

Single Technology Appraisal (STA) Anamorelin for treating cachexia and anorexia in people with non-small-cell lung cancer Single Technology Appraisal (STA) Anamorelin for treating cachexia and anorexia in people with non-small-cell Response to consultee and commentator comments on the draft remit and draft scope (pre-referral)

More information

Metabolic issues in nutrition: Implications for daily care

Metabolic issues in nutrition: Implications for daily care Metabolic issues in nutrition: Implications for daily care Ingvar Bosaeus Dept of Clinical Nutrition Sahlgrenska University Hospital Göteborg, Sweden Nutritional problems in cancer In western countries,

More information

Integration of Palliative and Oncology Care in patients with lung and other

Integration of Palliative and Oncology Care in patients with lung and other 1 Integration of Palliative and Oncology Care in patients with lung and other thoracic cancer: referral criteria and clinical care pathways. A. Caraceni, C. Brunelli, S. Lo Dico, E. Zecca, P. Bracchi,

More information

Ingvar Bosaeus, MD, Sahlgrenska University Hospital, Goteborg, Sweden

Ingvar Bosaeus, MD, Sahlgrenska University Hospital, Goteborg, Sweden Cachexia in Cancer Ingvar Bosaeus, MD, Sahlgrenska University Hospital, Goteborg, Sweden Severe, progressive malnutrition and wasting often is seen in advanced cancer, with weight loss long associated

More information

Molecular Mechanisms associated with the Cancer-Cachexia Syndrome

Molecular Mechanisms associated with the Cancer-Cachexia Syndrome Molecular Mechanisms associated with the Cancer-Cachexia Syndrome Prof. Dr. Josep M. Argilés Department of Biochemistry & Molecular Biology University of Barcelona, Spain Disclosures: DANONE (Scientific

More information

Cancer Cachexia. Current and Future Management Options

Cancer Cachexia. Current and Future Management Options Cancer Cachexia Current and Future Management Options Cancer Cachexia Overview Symptoms Pathophysiology Current Treatment Options New Drugs Cancer Cachexia Overview " the shoulders, clavicles, chest and

More information

ONO PHARMACEUTICAL CO., LTD. Corporate Communications

ONO PHARMACEUTICAL CO., LTD. Corporate Communications September 29, 2014 ONO PHARMACEUTICAL CO., LTD. Corporate Communications public_relations@ono.co.jp Helsinn Group, Switzerland, announced the results of Phase III Trials (ROMANA 1 and ROMANA 2) of Anamorelin/ONO-7643

More information

BAOJ Palliative medicine

BAOJ Palliative medicine Vol:, Issue: Abstract Randomised Controlled Trial of Fish Oil Supplement to Treat Cancer Cachexia Dewey A, Higgins B, Baughan C, Stores R, 4 Dean T, Sally Kilburn School of Health Sciences and Social Work,

More information

ProSure. Strength to Fight and Get Back to Life. Strength to Fight and Get Back to Life D1

ProSure. Strength to Fight and Get Back to Life. Strength to Fight and Get Back to Life D1 ProSure Strength to Fight and Get Back to Life ProSure. Strength to Fight and Get Back to Life 5004 1112 166 D1 Cancer care is evolving at an incredibly fast pace, and the prognosis for a person with cancer

More information

Prognostication in Advanced Cancer: A Study Examining an Inflammation-Based Score

Prognostication in Advanced Cancer: A Study Examining an Inflammation-Based Score Vol. 44 No. 2 August 2012 Journal of Pain and Symptom Management 161 Original Article Prognostication in Advanced Cancer: A Study Examining an Inflammation-Based Score Michael Partridge, MBChB, Marie Fallon,

More information

TITLE: Nutritional Supplementation for Patients with Cancer: A Review of the Clinical Effectiveness and Guidelines

TITLE: Nutritional Supplementation for Patients with Cancer: A Review of the Clinical Effectiveness and Guidelines TITLE: Nutritional Supplementation for Patients with Cancer: A Review of the Clinical Effectiveness and Guidelines DATE: 12 February 2014 CONTEXT AND POLICY ISSUES People with cancer who are well nourished

More information

LONDON CANCER NEW DRUGS GROUP RAPID REVIEW

LONDON CANCER NEW DRUGS GROUP RAPID REVIEW LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Abiraterone for the treatment of metastatic castration-resistant prostate cancer that has progressed on or after a docetaxel-based chemotherapy regimen Disease

More information

Malnutrition in advanced CKD

Malnutrition in advanced CKD Malnutrition in advanced CKD Malnutrition Lack of proper nutrition, caused by not having enough to eat, not eating enough of the right things or being unable to use the food that one does eat Jessica Stevenson

More information

Diet what helps? Lindsey Allan Macmillan Oncology Dietitian Royal Surrey County Hospital, Guildford

Diet what helps? Lindsey Allan Macmillan Oncology Dietitian Royal Surrey County Hospital, Guildford Diet what helps? Lindsey Allan Macmillan Oncology Dietitian Royal Surrey County Hospital, Guildford Diet and cancer Diet and cancer Nutrition research Lack of funding RCTs Low quality Small sample sizes

More information

American Journal of Clinical Nutrition July, 2004;80:204 16

American Journal of Clinical Nutrition July, 2004;80:204 16 1 Dietary intake of n 3 and n 6 fatty acids and the risk of prostate Cancer American Journal of Clinical Nutrition July, 2004;80:204 16 Michael F Leitzmann, Meir J Stampfer, Dominique S Michaud, Katarina

More information

Clinical Nutrition in the 21st Century Malnutrition, sarcopenia and cachexia

Clinical Nutrition in the 21st Century Malnutrition, sarcopenia and cachexia Clinical Nutrition in the 21st Century Malnutrition, sarcopenia and cachexia Stéphane M. Schneider, MD, PhD, FEBGH Professor of Nutrition and ESPEN ECPC Chair In proto-indo-european, Latin and Greek Under

More information

1st Abbott International Conference for Cancer Nutrition Therapy. Proceedings Booklet

1st Abbott International Conference for Cancer Nutrition Therapy. Proceedings Booklet 1st Abbott International Conference for Cancer Nutrition Therapy Proceedings Booklet The 1st Abbott International Conference for Cancer Nutrition Therapy April 12-14, 2010 The 1st Abbott International

More information

Integration of palliative care into oncology

Integration of palliative care into oncology 1 Integration of palliative care into oncology Stein Kaasa European Palliative Care Research Centre, Faculty of Medicine, NTNU and Department of Oncology, St. Olavs Hospital, Trondheim University Hospital

More information

Alterazioni metaboliche e nutrizionali in corso di artrite reumatoide e malattie autoimmuni Alessio Molfino, MD, PhD

Alterazioni metaboliche e nutrizionali in corso di artrite reumatoide e malattie autoimmuni Alessio Molfino, MD, PhD Alterazioni metaboliche e nutrizionali in corso di artrite reumatoide e malattie autoimmuni Alessio Molfino, MD, PhD Direttore: Prof. Filippo Rossi Fanelli alessio.molfino@uniroma1.it Rheumatoid arthritis

More information

Developing your Integrative Self-Care Plan

Developing your Integrative Self-Care Plan Developing your Integrative Self-Care Plan Erin Sweet ND, MPH, FABNO Assistant Research Scientist Bastyr University [PRESENTER PHOTO] Naturopathic Oncology Red Cedar Wellness Center & Orion Center for

More information

Syed H Jafri 1,2*, Runhua Shi 1,2 and Glenn Mills 1,2

Syed H Jafri 1,2*, Runhua Shi 1,2 and Glenn Mills 1,2 Jafri et al. BMC Cancer 2013, 13:158 RESEARCH ARTICLE Open Access Advance lung cancer inflammation index (ALI) at diagnosis is a prognostic marker in patients with metastatic non-small cell lung cancer

More information

Interprofessional Webinar Series

Interprofessional Webinar Series Interprofessional Webinar Series Management of Anorexia/Cachexia Ebtesam Ahmed, Pharm.D., M.S. Director of Pharmacy Internship MJHS Institute for Innovation in Palliative Care Associate Clinical Professor

More information

Cabazitaxel (XRP-6258) for hormone refractory, metastatic prostate cancer second line after docetaxel

Cabazitaxel (XRP-6258) for hormone refractory, metastatic prostate cancer second line after docetaxel Cabazitaxel (XRP-6258) for hormone refractory, metastatic prostate cancer second line after docetaxel April 2009 This technology summary is based on information available at the time of research and a

More information

Leveraging Prospective Cohort Studies to Advance Colorectal Cancer Prevention, Treatment and Biology

Leveraging Prospective Cohort Studies to Advance Colorectal Cancer Prevention, Treatment and Biology Leveraging Prospective Cohort Studies to Advance Colorectal Cancer Prevention, Treatment and Biology Charles S. Fuchs, MD, MPH Director, Yale Cancer Center Physician-in-Chief, Smilow Cancer Hospital New

More information

Advances in gastric cancer: How to approach localised disease?

Advances in gastric cancer: How to approach localised disease? Advances in gastric cancer: How to approach localised disease? Andrés Cervantes Professor of Medicine Classical approach to localised gastric cancer Surgical resection Pathology assessment and estimation

More information

Randomised phase III clinical trial of 5 different arms of treatment on 332 patients with cancer cachexia

Randomised phase III clinical trial of 5 different arms of treatment on 332 patients with cancer cachexia European Review for Medical and Pharmacological Sciences Randomised phase III clinical trial of 5 different arms of treatment on 332 patients with cancer cachexia G. MANTOVANI Department of Medical Oncology,

More information

Non-small cell lung cancer (NSCLC) remains the commonest

Non-small cell lung cancer (NSCLC) remains the commonest Original Article Clinical Utility of the Pretreatment Glasgow Prognostic Score in Patients with Advanced Inoperable Non-small Cell Lung Cancer Elaine Y.L. Leung, MB ChB,* Hazel R. Scott, MD, and Donald

More information

Cancer Cachexia: Beyond Weight Loss

Cancer Cachexia: Beyond Weight Loss Clinical Review Cancer Cachexia: Beyond Weight Loss Andrew R. Bruggeman, MD, Arif H. Kamal, MD, Thomas W. LeBlanc, MD, Joseph D. Ma, PharmD, Vickie E. Baracos, PhD, and Eric J. Roeland, MD University of

More information

Pharmacological treatments. Jann Arends Tumor Biology Center Freiburg, Germany

Pharmacological treatments. Jann Arends Tumor Biology Center Freiburg, Germany Pharmacological treatments Jann Arends Tumor Biology Center Freiburg, Germany Pharmacologic treatment: Basic concept Interfere with undesired physiology Drug a specific target Major problems in cachexia

More information

Themes. Evaluer (defini:on, diagnos:c criteria) Recherche clinique en cancérologie : quid du statut nutri:onnel? Agir Adapter 03/04/15

Themes. Evaluer (defini:on, diagnos:c criteria) Recherche clinique en cancérologie : quid du statut nutri:onnel? Agir Adapter 03/04/15 Recherche clinique en cancérologie : quid du statut nutri:onnel? Pierre Senesse, Laboratoire Epsylon, Ins:tut Régional du Cancer de Montpellier SIRIC Vickie Baracos, Department of Oncology, University

More information

Background 1. Comparative effectiveness of nintedanib

Background 1. Comparative effectiveness of nintedanib NCPE report on the cost effectiveness of nintedanib (Vargatef ) in combination with docetaxel for the treatment of adult patients with locally advanced, metastatic or locally recurrent non-small cell lung

More information

Omega-3 supplementation promotes key anti-inflammatory pathways that naturally support back, neck, and joint health and mobility

Omega-3 supplementation promotes key anti-inflammatory pathways that naturally support back, neck, and joint health and mobility n Promotes key anti-inflammatory pathways n Promotes joint mobility and flexibility n Is a natural adjunct to conventional therapies n Is safe for long-term use Omega-3 supplementation promotes key anti-inflammatory

More information

FROM ABSTRACT Patients with rheumatoid arthritis (RA) improve on a vegetarian diet or supplementation with fish oil.

FROM ABSTRACT Patients with rheumatoid arthritis (RA) improve on a vegetarian diet or supplementation with fish oil. Anti-inflammatory effects of a low arachidonic acid diet and fish oil in patients with rheumatoid arthritis Rheumatol Int (2003) 23: 27 36 Olaf Adam, Corinna Beringer, Thomas Kless, Christa Lemmen, Alexander

More information

The role of omega-3 fatty acids as a treatment for bipolar disorder

The role of omega-3 fatty acids as a treatment for bipolar disorder The role of omega-3 fatty acids as a treatment for bipolar disorder Research into omega-3 fatty acids as a possible treatment for mood disorders is a new and interesting area of research Although research

More information

There is more scientific evidence behind the cardiovascular benefits of fish oil than nearly any other nutritional supplement

There is more scientific evidence behind the cardiovascular benefits of fish oil than nearly any other nutritional supplement n Provides optimal support for heart health n Reduces triglyceride levels n Reduces cardiovascular risk factors 7, 8 n Complements statin drug therapy n Optimizes circulation and blood vessel function

More information

Basic pathophysiology of recovery: the role of endocrine metabolic response. Franco Carli McGill University Montreal, Canada

Basic pathophysiology of recovery: the role of endocrine metabolic response. Franco Carli McGill University Montreal, Canada Basic pathophysiology of recovery: the role of endocrine metabolic response Franco Carli McGill University Montreal, Canada ASER, Washington, 2016 postoperative recovery, 1950 Loss of body weight, less

More information

Cancer Anorexia Cachexia Syndrome

Cancer Anorexia Cachexia Syndrome Cancer Anorexia Cachexia Syndrome John Mulder, MD Chief Medical Consultant for Hospice and Palliative Care Holland Home Medical Director, Trillium Institute Grand Rapids, MI Cancer Cachexia - Definitions

More information

Leandro C.A. Cerchietti, Alfredo H. Navigante, and Monica A. Castro

Leandro C.A. Cerchietti, Alfredo H. Navigante, and Monica A. Castro NUTRITION AND CANCER, 59(1), 14 20 Copyright C 2007, Lawrence Erlbaum Associates, Inc. Effects of Eicosapentaenoic and Docosahexaenoic n-3 Fatty Acids From Fish Oil and Preferential Cox-2 Inhibition on

More information

Innovations in Nutritional Therapy for Cats with CKD Rebecca Mullis, DVM, DACVN

Innovations in Nutritional Therapy for Cats with CKD Rebecca Mullis, DVM, DACVN Innovations in Nutritional Therapy for Cats with CKD Rebecca Mullis, DVM, DACVN Content presented at the 2017 Hill s Global Symposium in Washington D.C., May 5-6, 2017. Chronic kidney disease (CKD) is

More information

Lifestyle Factors and Cancer Survivorship: Observational Findings of Weight, Physical Activity, and Diet on Survival

Lifestyle Factors and Cancer Survivorship: Observational Findings of Weight, Physical Activity, and Diet on Survival Lifestyle Factors and Cancer Survivorship: Observational Findings of Weight, Physical Activity, and Diet on Survival Melinda L. Irwin, PhD, MPH Associate Professor of Epidemiology Yale School of Medicine

More information

University of Cagliari, Cagliari, Italy

University of Cagliari, Cagliari, Italy The Oncologist Symptom Management and Supportive Care Randomized Phase III Clinical Trial of Five Different Arms of Treatment in 332 Patients with Cancer Cachexia GIOVANNI MANTOVANI, a ANTONIO MACCIÒ,

More information

Physical activity, Obesity, Diet and Colorectal Cancer Prognosis. Jeffrey Meyerhardt, MD, MPH Dana-Farber Cancer Institute Boston, MA

Physical activity, Obesity, Diet and Colorectal Cancer Prognosis. Jeffrey Meyerhardt, MD, MPH Dana-Farber Cancer Institute Boston, MA Physical activity, Obesity, Diet and Colorectal Cancer Prognosis Jeffrey Meyerhardt, MD, MPH Dana-Farber Cancer Institute Boston, MA Colorectal Cancer Incidence ~148,000 cases in US annually and ~50,000

More information

Renal cachexia. Professor Joanne Reid

Renal cachexia. Professor Joanne Reid Renal cachexia Professor Joanne Reid Cachexia Cachexia is a complex metabolic syndrome associated with underlying illness and characterised by muscle loss, with or without loss of fat Definition of cachexia

More information

Nutrition and oncology: medical aspects. Case history. What is cancer? Head, Palliative Care RPAH/Sydney Cancer Centre May 2008

Nutrition and oncology: medical aspects. Case history. What is cancer? Head, Palliative Care RPAH/Sydney Cancer Centre May 2008 utrition and oncology: medical aspects? Clin Assoc Prof. Paul Glare, FRACP Head, Palliative Care RPAH/Sydney Cancer Centre May 2008 Case history What is cancer? 24M PH IDU, HCV 1/08: bowel obstruction:

More information

Management Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective

Management Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective Management Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective Julie R. Brahmer, M.D. Associate Professor of Oncology The Sidney Kimmel Comprehensive

More information

ABC of palliative care: Anorexia, cachexia, and nutrition

ABC of palliative care: Anorexia, cachexia, and nutrition BMJ 1997;315:1219-1222 (8 November) Clinical review ABC of palliative care: Anorexia, cachexia, and nutrition Eduardo Bruera Top Does the patient have... Why is the patient... Cachexia is a complex syndrome

More information

Pharmacological management of cachexia in adult cancer patients: a systematic review of clinical trials

Pharmacological management of cachexia in adult cancer patients: a systematic review of clinical trials Advani et al. BMC Cancer (2018) 18:1174 https://doi.org/10.1186/s12885-018-5080-4 RESEARCH ARTICLE Open Access Pharmacological management of cachexia in adult cancer patients: a systematic review of clinical

More information

Infographic (right): ESMO 2014 record breaking Congress

Infographic (right): ESMO 2014 record breaking Congress ESMO 2014 Congress Scientific Meeting Report Supportive and Palliative Care Extract 26-30 September 2014 Madrid, Spain Summary The European Society for Medical Oncology (ESMO) Congress, held September

More information

TPN and lipid. RCT of 57 patients. TPN with lipid vs TPN without lipid. TPN associated with increased infectious complications

TPN and lipid. RCT of 57 patients. TPN with lipid vs TPN without lipid. TPN associated with increased infectious complications TPN and lipid RCT of 57 patients TPN with lipid vs TPN without lipid TPN associated with increased infectious complications * * * * Battistella FD, et al. J Trauma 1997; 43:52. Data Needed 1. New TPN trials

More information

Are palliative cancer patients willing and able to participate in a physical exercise program?

Are palliative cancer patients willing and able to participate in a physical exercise program? Palliative and Supportive Care ~2005!, 3, 281 287. Printed in the USA. Copyright 2005 Cambridge University Press 1478-9515005 $16.00 DOI: 10.10170S1478951505050443 Are palliative cancer patients willing

More information

ESPEN Congress Leipzig 2013

ESPEN Congress Leipzig 2013 ESPEN Congress Leipzig 2013 Nutrition and cancer: impact on outcome Survival, quality of life, reduced toxicity: what can be achieved in cancer patients? M.A.E. van Bokhorst - de van der Schueren (NL)

More information

O ρόλος της διατροφής κατά τη θεραπεία του καρκίνου

O ρόλος της διατροφής κατά τη θεραπεία του καρκίνου O ρόλος της διατροφής κατά τη θεραπεία του καρκίνου I. Gioulbasanis MD, PhD Dept. of Chemotherapy Larissa General Clinic E. Patsidis INTRODUCTION Καρκινογένεση Ενεργός Νόσος Επιβιώσαντες με καρκίνο (cancer

More information

Programme overview (subject to change)

Programme overview (subject to change) Programme overview (subject to change) Time 0800-0900 Premiminary programme - Thursday 7 June Olavshallen 1204 seats Olav Tryggvasson 325 seats Haraldsalen 140 seats Tavern/ Brattøra 210 seats 0900-1100

More information

Y A L E S C H O O L O F M E D I C I N E. This is a CME accredited activity. The presenters and there are no conflicts of interest.

Y A L E S C H O O L O F M E D I C I N E. This is a CME accredited activity. The presenters and there are no conflicts of interest. This is a CME accredited activity. The presenters and there are no conflicts of interest. Pain in Pancreatic Cancer More than 50% of patients with pancreatic cancer suffer from abdominal and back pain

More information

ESPEN Congress The Hague 2017

ESPEN Congress The Hague 2017 ESPEN Congress The Hague 2017 Altering lifestyle to improve nutritional status in older adults Nutritional interventions to prevent and treat frailty F. Landi (IT) Nutritional interventions to prevent

More information

Case 1 Metastatic Pancreatic Adenocarcinoma: What Therapy Should I Select First?

Case 1 Metastatic Pancreatic Adenocarcinoma: What Therapy Should I Select First? Case 1 Metastatic Pancreatic Adenocarcinoma: What Therapy Should I Select First? Marc Peeters, MD, PhD Head of the Oncology Department Antwerp University Hospital Antwerp, Belgium marc.peeters@uza.be 71-year-old

More information

risks. Therefore, perc agreed that the reimbursement criteria should match the eligibility criteria of the SELECT trial.

risks. Therefore, perc agreed that the reimbursement criteria should match the eligibility criteria of the SELECT trial. risks. Therefore, perc agreed that the reimbursement criteria should match the eligibility criteria of the SELECT trial. perc considered input from one patient advocacy group indicating that patients value

More information

LONDON CANCER NEW DRUGS GROUP RAPID REVIEW. Erlotinib for the third or fourth-line treatment of NSCLC January 2012

LONDON CANCER NEW DRUGS GROUP RAPID REVIEW. Erlotinib for the third or fourth-line treatment of NSCLC January 2012 Disease background LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Erlotinib for the third or fourth-line treatment of NSCLC January 2012 Lung cancer is the second most common cancer in the UK (after breast),

More information

Diet in cancer. When good cells go bad

Diet in cancer. When good cells go bad Diet in cancer When good cells go bad What is cancer? Cancer means Crab for the creeping way in which it spreads It is a general term for more than 100 types of malignant neoplastic disease Cancer not

More information

NICE Quality Standards and COF

NICE Quality Standards and COF NICE Quality Standards and COF David Baldwin Consultant Respiratory Physician NUH Hon Senior Lecturer Nottingham University Clinical lead NICE lung cancer GL Chair NICE QS Topic Expert Group Quality Standards

More information

Cachexia. Disease settings. Mechanism. From Wikipedia, the free encyclopedia

Cachexia. Disease settings. Mechanism. From Wikipedia, the free encyclopedia Cachexia From Wikipedia, the free encyclopedia Cachexia (/kəkɛksiə/; from Greek κακός kakos "bad" and ἕξις hexis "condition") [1] or wasting syndrome is loss of weight, muscle atrophy, fatigue, weakness,

More information

Prognostic significance of K-Ras mutation rate in metastatic colorectal cancer patients. Bruno Vincenzi Università Campus Bio-Medico di Roma

Prognostic significance of K-Ras mutation rate in metastatic colorectal cancer patients. Bruno Vincenzi Università Campus Bio-Medico di Roma Prognostic significance of K-Ras mutation rate in metastatic colorectal cancer patients Bruno Vincenzi Università Campus Bio-Medico di Roma Colorectal cancer 3 rd most common cancer worldwide Approximately

More information

A Population-Based Study on the Uptake and Utilization of Stereotactic Radiosurgery (SRS) for Brain Metastasis in Nova Scotia

A Population-Based Study on the Uptake and Utilization of Stereotactic Radiosurgery (SRS) for Brain Metastasis in Nova Scotia A Population-Based Study on the Uptake and Utilization of Stereotactic Radiosurgery (SRS) for Brain Metastasis in Nova Scotia Gaurav Bahl, Karl Tennessen, Ashraf Mahmoud-Ahmed, Dorianne Rheaume, Ian Fleetwood,

More information

2 nd line Therapy and Beyond NSCLC. Alan Sandler, M.D. Oregon Health & Science University

2 nd line Therapy and Beyond NSCLC. Alan Sandler, M.D. Oregon Health & Science University 2 nd line Therapy and Beyond NSCLC Alan Sandler, M.D. Oregon Health & Science University Treatment options for advanced or metastatic (stage IIIb/IV) NSCLC Suitable for chemotherapy Diagnosis Unsuitable/unwilling

More information

Nutritional support in multimodal therapy for cancer cachexia

Nutritional support in multimodal therapy for cancer cachexia Support Care Cancer (2008) 16:447 451 DOI 10.1007/s00520-007-0388-7 REVIEW ARTICLE Nutritional support in multimodal therapy for cancer cachexia Ingvar Bosaeus Received: 27 June 2007 / Accepted: 5 December

More information

Cetoleic acid makes pelagic fish more healthy

Cetoleic acid makes pelagic fish more healthy Cetoleic acid makes pelagic fish more healthy WORKSHOP IN FISHMEAL AND FISH OIL, NOVEMBER 2018 Bente Ruyter Nofima Omega-3 fatty acids and health Eye Brain Cell membrane The marine omega-3 fatty acids

More information

Scientific Product Rationale

Scientific Product Rationale Scientific Product Rationale Supportan & Supportan DRINK Enteral Nutrition Formula Adapted to the Special Needs of Cancer Patients Tube & Sip Feed for Supplemental or Complete Nutrition Food for Special

More information

Breast SSG Education Event Anglia Cancer Network Sally Donaghey Macmillan AHP Lead

Breast SSG Education Event Anglia Cancer Network Sally Donaghey Macmillan AHP Lead Breast SSG Education Event Anglia Cancer Network 10.2.2012 Sally Donaghey Macmillan AHP Lead sally.donaghey@suffolk.pct.nhs.uk IPx People affected by cancer need information that is timely, relevant, and

More information

Prophylactic Cranial Irradiation and Thoracic Radiotherapy in Extensive Stage Small-Cell Lung Cancer

Prophylactic Cranial Irradiation and Thoracic Radiotherapy in Extensive Stage Small-Cell Lung Cancer Prophylactic Cranial Irradiation and Thoracic Radiotherapy in Extensive Stage Small-Cell Lung Cancer Dr Neil Bayman Consultant Clinical Oncology ESMO-Christie Preceptorship Programme in Lung Cancer, March

More information

PROGESTINS AHFS 68:32

PROGESTINS AHFS 68:32 PROGESTINS AHFS 68:32 Class: Sex hormones. Indications: Hormone therapy in breast (megestrol), renal (medroxyprogesterone) and endometrial cancers, anorexia and cachexia (megestrol), postcastration hot

More information

status should be eligible for treatment with atezolizumab. perc acknowledged the small number of patients with an EGFR or ALK mutation positive disease recruited on the trials but agreed that the overall

More information

Anaemia & Cancer. John de Vos Consultant Haematologist RSCH

Anaemia & Cancer. John de Vos Consultant Haematologist RSCH Anaemia & Cancer John de Vos Consultant Haematologist RSCH overview Definitions & setting the scene Causes Consequences Biology Treatment Personal approach Patient Clinical team Anaemia - Definition :

More information

Background Comparative effectiveness of nivolumab

Background Comparative effectiveness of nivolumab NCPE report on the cost effectiveness of nivolumab (Opdivo ) for the treatment of locally advanced or metastatic squamous non-small cell lung cancer after prior chemotherapy in adults. The NCPE has issued

More information

LONDON CANCER NEW DRUGS GROUP RAPID REVIEW. Update on high dose imatinib for gastrointestinal stromal tumour (GIST) harbouring KIT exon 9 mutations

LONDON CANCER NEW DRUGS GROUP RAPID REVIEW. Update on high dose imatinib for gastrointestinal stromal tumour (GIST) harbouring KIT exon 9 mutations LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Update on high dose imatinib for gastrointestinal stromal tumour (GIST) harbouring KIT exon 9 mutations Summary Date prepared: May 2012 Imatinib was the first

More information

Name of Policy: Measurement of Long-Chain Omega-3 Fatty Acids in Red Blood Cell Membranes as a Cardiac Risk Factor

Name of Policy: Measurement of Long-Chain Omega-3 Fatty Acids in Red Blood Cell Membranes as a Cardiac Risk Factor Name of Policy: Measurement of Long-Chain Omega-3 Fatty Acids in Red Blood Cell Membranes as a Cardiac Risk Factor Policy #: 239 Latest Review Date: July 2010 Category: Laboratory Policy Grade: Active

More information

Section Editor Steven T DeKosky, MD, FAAN Kenneth E Schmader, MD

Section Editor Steven T DeKosky, MD, FAAN Kenneth E Schmader, MD Prevention of dementia Author Daniel Press, MD Michael Alexander, MD Section Editor Steven T DeKosky, MD, FAAN Kenneth E Schmader, MD Deputy Editor Janet L Wilterdink, MD Last literature review version

More information

PACLitaxel Monotherapy 80mg/m 2 7 days

PACLitaxel Monotherapy 80mg/m 2 7 days INDICATIONS FOR USE: PACLitaxel Monotherapy 80mg/m 2 7 days INDICATION ICD10 Regimen Code *Reimbursement Status Treatment of metastatic breast carcinoma (mbc) in patients C50 00226a Hospital who have either

More information

Dr Ahmad Shaltut Othman Anaesthesiologist & Intensivist Hosp Sultanah Bahiyah Alor Setar

Dr Ahmad Shaltut Othman Anaesthesiologist & Intensivist Hosp Sultanah Bahiyah Alor Setar FEEDING WITH FISH OIL Dr Ahmad Shaltut Othman Anaesthesiologist & Intensivist Hosp Sultanah Bahiyah Alor Setar New horizons in clinical nutrition from Support to Therapy Landmarks in Parenteral Nutrition

More information

Nutritional Support in the Perioperative Period

Nutritional Support in the Perioperative Period Nutritional Support in the Perioperative Period Topic 17 Module 17.3 Nutritional Support in the Perioperative Period Ken Fearon Learning Objectives Understand the principles behind nutritional care for

More information

New targets in endometrial and ovarian cancer

New targets in endometrial and ovarian cancer New targets in endometrial and ovarian cancer SAMO Interdisciplinary Workshop on Gynecologic Tumors Luzern, January 16-17, 2016 C. Sessa IOSI Bellinzona Outline New targets in ovarian cancer - Cell cycle

More information

International Graduate Course in Exercise & Clinical Physiology

International Graduate Course in Exercise & Clinical Physiology International Graduate Course in Exercise & Clinical Physiology Exercise and Cancer A view to the future through the eyes of the past Robert D. Kilgour, Ph.D., FACSM Professor & Chair Department of Exercise

More information

Sarcopenia - a Regulatory Perspective

Sarcopenia - a Regulatory Perspective Sarcopenia - a Regulatory Perspective Dragos Roman, M.D. Team Leader Division of Metabolism and Endocrinology Products, Office of New Drugs, Center for Drug Evaluation and Research, FDA May 11, 2012 1

More information